Company Overview

Kopran Limited filed its Annual Report for FY 2025-26 and audited financial statements, reporting mixed financial performance with revenue growth but significant profit decline.

Financial Performance

Consolidated Results (₹ Lakhs): Revenue grew 8.23% to ₹68,142.36 from ₹62,960.44 in FY25, while net profit declined 33.26% to ₹2,573.12 from ₹3,855.19. The decline was primarily due to forex losses of ₹1,595 lakhs and higher depreciation.

Standalone Performance: Revenue increased 12.78% to ₹30,564.62 lakhs with profit growth of 13.19% to ₹3,039.97 lakhs, showing stronger operational performance at the parent company level.

Segment Analysis

  • Formulations Business: ₹29,639 lakhs revenue (Penicillin Plant: ₹17,509 lakhs; Non-Penicillin Plant: ₹12,130 lakhs)
  • API Business (via subsidiary KRLL): ₹37,335 lakhs revenue, up 3.49% (Carbapenem: ₹18,977 lakhs; Macrolide: ₹6,081 lakhs; Anti-Infective: ₹4,580 lakhs)
  • Geographical Revenue: Significant exposure to South Africa (₹12,628.01 lakhs), Ethiopia (₹7,982.45 lakhs), and other international markets

Dividend & Capital Structure

The Board recommended a final dividend of ₹3.00 per share (30%), subject to shareholder approval at the 67th AGM scheduled for August 18, 2026. This would result in cash outflow of approximately ₹1,448.57 lakhs.

Key Developments

  • Panoli API Facility: Commercial production commenced on March 31, 2026, expected to ramp up over 2-3 years after regulatory approvals
  • CDMO/CMO Agreements: New partnerships signed with international pharma companies to enhance regulated market exports
  • Amalgamation Scheme: Progress on scheme to amalgamate Kopran Laboratories Limited with share swap ratio of 100:45

Risk Management & Audit Matters

Foreign Currency Exposure: Significant receivables in USD (₹10,429.89 lakhs), EURO (₹926.82 lakhs), and GBP (₹1,268.09 lakhs), managed through hedging instruments (₹10,542.31 lakhs forward contracts).

Key Audit Matters: Auditors identified inventory valuation (₹16,420.78 lakhs) and trade receivables allowance (₹13,257.94 lakhs) as critical areas requiring significant judgment.

Corporate Governance & Compliance

  • Board Composition: 5 directors (1 executive, 4 non-executive including 3 independent directors)
  • CSR Spending: ₹83.53 lakhs spent against obligation of ₹60.54 lakhs
  • Credit Ratings: CRISIL BBB+/A2 (with watch developing) for both Kopran Ltd. and subsidiary KRLL
  • Tax Litigation: Disputed demands totaling ₹1,210.19 lakhs across various tax matters

Forward Outlook

The company is positioned for growth through backward integration, capacity expansion, and CDMO/CMO partnerships, with the Panoli facility expected to improve utilization as regulatory approvals are received.